Dai et al 2025 — Green-light analgesia mechanism mini-review

One-paragraph summary

Mini-review consolidating the cellular and molecular mechanisms underlying green-light analgesia, with explicit attention to the prolonged analgesic effect that persists after green-light exposure ends. The review identifies peripheral and central mechanisms: (1) inhibition of inflammatory response; (2) activation of the endogenous cannabinoid system; (3) nerve circuits between the lateral geniculate nucleus and other brain regions, including the dorsal raphe nucleus and rostral ventromedial medulla (RVM) — the canonical descending pain-modulation pathway. The review notes that the antinociceptive effect of green light has been proven in fibromyalgia and migraine patients but has not yet been reported in clinical settings for neuropathic pain — proposing future trial work in this indication. Green-light parameters (intensity, duration, wavelength) used in clinical trials are summarized. For the project, this paper consolidates the mechanism framing for the v0.3.1 §12.7 green-light arm and explicitly anchors the descending-inhibition-pathway involvement that connects green-light analgesia to the project's pre-existing descending_inhibition_failure mechanism entity. The dorsal raphe + RVM circuit involvement is the missing-link finding that connects visual-input modulation to the project's central-sensitization framework.

Claims as triples

• green_light_exposure — modulates → descending_inhibition_failure [evidence: nerve-circuit involvement of lateral geniculate nucleus → dorsal raphe nucleus + RVM; confidence: emerging]
• green_light_exposure — modulates → endocannabinoid_system [evidence: review consolidation; confidence: emerging (reinforces O'Brien 2025)]
• green_light_exposure — modulates → neuroinflammation_glial [evidence: peripheral + central inflammatory-response inhibition review; confidence: emerging]
• green_light_exposure — bridges → fm_central_only [evidence: review acknowledges proven antinociceptive effect in FM patients; confidence: emerging]

Methods note

Mini-review. Synthesizes preclinical and clinical literature on green-light analgesia mechanisms. Focus on persistence of analgesic effect post-exposure, cellular and molecular mechanisms, and clinical-trial parameter summary. Proposes future research directions in neuropathic pain.

Limitations

• Review-level evidence — no new primary data. The strength of the review is its consolidation framing rather than novel finding.
• Mechanism pluralism: peripheral inflammation, central endocannabinoid, descending inhibition all proposed simultaneously without adjudication. The relative contribution of each mechanism is not resolved.
• FM-direct framing is brief. The paper acknowledges FM as a green-light-responsive condition but the review's primary focus is neuropathic pain (the proposed future indication).

Open questions raised

• Which of the three proposed mechanisms (inflammation inhibition, endocannabinoid activation, descending-inhibition activation) dominates green-light analgesia in FM specifically? May differ from the OA model where O'Brien et al 2025 identifies endocannabinoid system as required.
• Does the prolonged-after-exposure analgesia reflect neuroplastic changes in the visual cortex → thalamic → descending-inhibition circuit (per the Tan et al 2025 V2M-LP finding) rather than sustained acute mechanism?
• Can the green-light analgesic effect be enhanced by co-administered descending-inhibition agonists (duloxetine, milnacipran) or compromised by descending-inhibition antagonists?

Triangulation notes

• Connects v0.3.1 §12.7 green-light arm to the project's descending-inhibition mechanism framework. The project's descending_inhibition_failure entity is established-tier (multiple FM literatures); this paper places green-light analgesia inside that framework via the lateral geniculate → dorsal raphe / RVM circuit.
• Compatible with O'Brien 2025 PAIN endocannabinoid mechanism — both papers identify endocannabinoid system as central. This paper adds descending-inhibition pathway as parallel mechanism.
• Compatible with Tan et al 2025 Commun Biol (ingested simultaneously) — both papers implicate visual-cortex-to-thalamic circuits in pain modulation. Together they establish a candidate neural-circuit framework.
• Compatible with the v0.3.1 §12.7 resveratrol arm — both green light and resveratrol operate via central mechanisms compatible with the HERV-mito loop's downstream effector arm.

Bridges

• B21 candidate strengthened — green-light therapy ↔ FM via descending-inhibition + endocannabinoid system + central inflammation-modulation triad.
• Connects to existing descending_inhibition_failure mechanism — green light becomes a candidate non-pharmacological activator of the descending-inhibition pathway, complementing duloxetine/milnacipran's pharmacological mechanism.